Nuvilex - NVLX

Nuvilex (NVLX)
Coverage: March 1, 2013 - March 1, 2014
Featured: March 1, 2013

Latest Newsletter Editions

spacer
Fri, May 30, 2014 @ 09:05 am
Nuvilex (NVLX): Don't Be Fooled By Quiet Trading It's been a rather quiet week on the trading front for Nuvilex (NVLX), but it's anything but quiet on the corporate front. It's...
Thu, May 1, 2014 @ 09:05 am
Nuvilex (NVLX): Proving My Theory Today The last edition I published on Nuvilex (NVLX) back on April 19th suggested we had finally...
Sat, Apr 19, 2014 @ 11:04 am
Nuvilex (NVLX): Now, The News Matters Lately I've made couple of predictions on Nuvilex (NVLX)- our biggest winner over the past...
Wed, Apr 9, 2014 @ 10:04 am
It Happens Two or Three Times A Year Clearly Nuvilex (NVLX) is, so far, the stock of the year for the OTC Journal. Since Mid January...
Tue, Apr 1, 2014 @ 02:04 pm
Nuvilex (NVLX): A Huge Step Towards Clinical Trials Lost in all the controversy about Nuvilex (NVLX) and its potential upside...

Click Here For More Newsletters on NVLX

spacer

Latest Blog Entries

spacer

Quote Data

spacer
Last Trade: 0.23 Bid: 0.0000
Last Size: 2,500 Ask: 0.0000
Trade Time: 3:57pm Bid x Ask Size: N/A
Change: up arrow +0.0140 (+6.48%) Day's Range: 0.21 - 0.23
Prev Close: 0.2160 52wk Range: 0.10 - 0.62
Open: 0.2150 P/E (ttm): N/A
Volume: 1,640,299 EPS (ttm): -0.047
spacer [Chart]

Business Summary

spacer

Disclosure

spacer
MarketBtye LLC was formerly paid a fee of $10,000 and 1 million newly issued restricted shares of Nuvilex by the company for six months of coverage. The 6 months has expired. On November 1, 2013, MarketByte LLC entered into a consulting agreement with Nuvilex to cover the company for an additional 6 months and received 300,00 newly issued restricted shares. MarketByte LLC currently holds no shares of Nuvilex, and has received $83,155.83 in proceed from sales of NVLX in 2014. At present, MarketByte LLC has no contractual obligation to provide coverage of Nuvilex. Therefore, there are no conflicts of interest.

Recent News Headlines

spacer
Nuvilex Begins Preclinical Studies With Translational Drug Development to Determine if Nuvilex's Unique Cancer Treatment Can Slow Accumulation of Malignant Ascites Fluid
Wed, 20 Aug 2014 13:00:00 GMT
[GlobeNewswire] - SILVER SPRING, Md. -- Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage, international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that studies ...
Nuvilex Announces Publication of Combined Results of the Initial Phase 1/2 Clinical Trial and a Second Phase 2 Clinical Trial of the Cell-in-a-Box(R) Plus Ifosfamide Combination in Patients With Advanced, Inoperable Pancreatic Cancer
Thu, 14 Aug 2014 13:00:00 GMT
[GlobeNewswire] - SILVER SPRING, Md. -- Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage, international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that its ...
Nuvilex Provides Update on Status of Preclinical Studies at Translational Drug Development
Wed, 13 Aug 2014 13:00:00 GMT
[GlobeNewswire] - SILVER SPRING, Md. -- Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage, international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that it ...
NUVILEX, INC. Financials
Sat, 09 Aug 2014 17:04:11 GMT
Nuvilex Announces That Dr. Richard M. Hyslop Will Present at the ACS Annual Meeting on "Sustainable, Green Chemistry and Medicine: Targeted Cannabinoid-Based Chemotherapy Utilizing Cell-in-a-Box(R) Live Cell Encapsulation Technology."
Mon, 04 Aug 2014 13:45:50 GMT
[GlobeNewswire] - SILVER SPRING, Md. -- Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage, international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that Dr. ...
NUVILEX, INC. Files SEC form 10-K, Annual Report
Mon, 04 Aug 2014 12:12:35 GMT
Nuvilex Nears Crucial Quality of Life Study in Malignant Ascites Associated with Pancreatic and Other Abdominal Cancers
Wed, 23 Jul 2014 04:00:00 GMT
[Accesswire] - New York, NY / ACCESSWIRE / July 23, 2014 / Nuvilex, Inc. (OTCQB: NVLX) will begin preclinical studies in early August with its Contract Research Organization (CRO) Translational Drug Development (TD2) ...
Cannabis Stocks Edge Higher Last Week Led by Nuvilex & Entertopia
Tue, 22 Jul 2014 13:30:00 GMT
[Accesswire] - WHITEFISH, MT / July 22, 2014 / The Marijuana Index(TM) moved slightly higher last week, despite a 7% drop in GW Pharmaceuticals plc (NASDAQ: GWPH) shares. Medbox Inc. (OTC: MDBX), the second largest component ...
Nuvilex and Austrianova Announce Results of Clinical Trial in Dogs with Mammary Tumors Treated With Cell-in-a-Box(R) Plus Cyclophosphamide
Thu, 17 Jul 2014 13:00:00 GMT
[GlobeNewswire] - SILVER SPRING, Md. -- Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage, international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, today announced, in cooperation ...
Cannabis Stocks Move Higher as Washington State Pot Sales Begin
Mon, 14 Jul 2014 13:30:00 GMT
[Accesswire] - WHITEFISH, MT / July 14, 2014 / The Marijuana Index(TM) moved higher last week in the aggregate, despite a 13% drop in GW Pharmaceuticals plc (NASDAQ: GWPH) shares and a roughly 1.5% drop in Medbox Inc. ...
Nuvilex Provides Shareholder Update on Milestone Accomplishments
Mon, 14 Jul 2014 13:00:00 GMT
[GlobeNewswire] - SILVER SPRING, Md. -- Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage, international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, today issued the following ...
Nuvilex Scheduled to Begin Preclinical Studies in Early August
Wed, 09 Jul 2014 13:00:00 GMT
[GlobeNewswire] - SILVER SPRING, Md. -- Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that all ...
Nuvilex Eyeing Partnership for Its Share of Future $114 Billion Diabetes Market
Mon, 07 Jul 2014 13:00:00 GMT
[Marketwired] - Nuvilex, Inc. announced last week that its executives recently met with the company's "global development partners" at the 2014 BIO International Convention in San Diego. One of the meetings ...
Nuvilex Executives Attend 2014 BIO International Convention
Tue, 01 Jul 2014 13:00:00 GMT
[GlobeNewswire] - SILVER SPRING, Md. -- Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that Chief ...
Nuvilex Inc., TD2 and the PCRT Should Draw Great Interest to the Company's Pancreatic Cancer Treatment
Fri, 20 Jun 2014 13:00:00 GMT
[Marketwired] - Nuvilex, Inc. can accomplish more in its upcoming preclinical trials than many may realize. With the announcement that Translational Drug Development will be conducting the preclinical studies and clinical ...
Nuvilex Heads to the Clinic With an Opportunity to Treat a Wider Range of Cancers
Thu, 12 Jun 2014 13:00:00 GMT
[Marketwired] - Nuvilex, Inc. and its shareholders should soon experience an event that, to date, has not been enjoyed by the Maryland biotech firm. With preclinical studies set to begin any day now at Translational Drug ...
Maple Leaf Green World Ahead of the Game with Production Scale, Know-How
Thu, 05 Jun 2014 13:30:00 GMT
[Accesswire] - Whitefish, MT / June 5, 2014 / Maple Leaf Green World's (CVE: MGW) (OTC: MPEFF) recent signature of an agreement to lease Woodmere Nursery's 7-acre Telkwa, B.C. greenhouse facility (with an option to purchase ...
Nuvilex CEO and COO Discuss Preclinical and Clinical Trials, Orphan Drug Status, Funding and Much More in Interview
Wed, 04 Jun 2014 12:30:00 GMT
[Marketwired] - Nuvilex, Inc. President and CEO Kenneth Waggoner and COO Dr. Gerald Crabtree addressed a number of topics associated with the company's pancreatic cancer treatment in an interview with Stock Market Media ...
Nuvilex Now Has Access to $50 Million With New Banking Agreement
Mon, 02 Jun 2014 13:00:00 GMT
[Marketwired] - Nuvilex has become quite a busy biotechnology firm of late, and with the announcement of what is now a "two-pronged attack" on pancreatic cancer, the company will most certainly need more money ...
NUVILEX, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material Definitive Ag
Thu, 29 May 2014 10:01:02 GMT